GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaron Beijing Co Ltd (HKSE:03759) » Definitions » EV-to-FCF

Pharmaron Beijing Co (HKSE:03759) EV-to-FCF : 88.54 (As of Jun. 24, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Pharmaron Beijing Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pharmaron Beijing Co's Enterprise Value is HK$37,582 Mil. Pharmaron Beijing Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was HK$424 Mil. Therefore, Pharmaron Beijing Co's EV-to-FCF for today is 88.54.

The historical rank and industry rank for Pharmaron Beijing Co's EV-to-FCF or its related term are showing as below:

HKSE:03759' s EV-to-FCF Range Over the Past 10 Years
Min: -3479.85   Med: -70.99   Max: 1353.73
Current: 89.61

During the past 10 years, the highest EV-to-FCF of Pharmaron Beijing Co was 1353.73. The lowest was -3479.85. And the median was -70.99.

HKSE:03759's EV-to-FCF is ranked worse than
87.56% of 402 companies
in the Biotechnology industry
Industry Median: 5.935 vs HKSE:03759: 89.61

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-24), Pharmaron Beijing Co's stock price is HK$9.08. Pharmaron Beijing Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was HK$0.908. Therefore, Pharmaron Beijing Co's PE Ratio for today is 10.00.


Pharmaron Beijing Co EV-to-FCF Historical Data

The historical data trend for Pharmaron Beijing Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaron Beijing Co EV-to-FCF Chart

Pharmaron Beijing Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 203.33 279.19 -3,236.13 -105.52 -497.55

Pharmaron Beijing Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -77.20 -86.20 -278.38 -497.55 102.90

Competitive Comparison of Pharmaron Beijing Co's EV-to-FCF

For the Biotechnology subindustry, Pharmaron Beijing Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmaron Beijing Co's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Pharmaron Beijing Co's EV-to-FCF falls into.



Pharmaron Beijing Co EV-to-FCF Calculation

Pharmaron Beijing Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=37582.490/424.452
=88.54

Pharmaron Beijing Co's current Enterprise Value is HK$37,582 Mil.
Pharmaron Beijing Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$424 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmaron Beijing Co  (HKSE:03759) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Pharmaron Beijing Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=9.08/0.908
=10.00

Pharmaron Beijing Co's share price for today is HK$9.08.
Pharmaron Beijing Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0.908.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Pharmaron Beijing Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Pharmaron Beijing Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmaron Beijing Co (HKSE:03759) Business Description

Traded in Other Exchanges
Address
No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Hong Kong, HKG
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services; Clinical development services and biologics and CGT services. The company generates maximum revenue from Laboratory services segment.
Executives
Morgan Stanley 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
The Bank Of New York Mellon Corporation 2201 Interest of corporation controlled by you
Citigroup Inc. 2201 Interest of corporation controlled by you
Blackrock, Inc. 2201 Interest of corporation controlled by you
Gic Private Limited 2102 Investment manager
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Matthews International Capital Management, Llc 2102 Investment manager
First H Share Award And Scheme Of Pharmaron Beijing Co., Ltd. 2301 Trustee
Kastle Limited 2301 Trustee
Jian Xin Bei Jing Tou Zi Ji Jin Guan Li You Xian Ze Ren Gong Si 2201 Interest of corporation controlled by you
Jian Xin Xin Tuo You Xian Ze Ren Gong Si 2201 Interest of corporation controlled by you

Pharmaron Beijing Co (HKSE:03759) Headlines

No Headlines